Led drug development efforts that resulted in six drug approvals, including Chiasma’a oral octreotide; board member of other companies that received two additional approvals
Earlier experience: CFO of Regeneron, the founder of the strategy consulting firm RxFDP, and VP of Pfizer Pharmaceuticals
Co-inventor of 18 issued US patents
BA from Dartmouth College, and an MBA from the Wharton School, University of Pennsylvania
Co-Founder of Sedor Pharmaceuticals (successful exit), holds C-level positions in BioMed Valley Discoveries, Pax Neuroscience
Advisor in Life Sciences to Marathon Asset Management
Founder of Frankel Group LLC, a global life science strategy consulting firm (successful exit to Huron Consulting/Oliver Wyman)
Partner and President of SJ Weinstein Associates Inc., a healthcare advertising and marketing strategy firm (successful exit to Bates Healthcare)
Senior management positions at Pfizer Pharmaceuticals in business planning, and marketing management
Senior Research Officer for Citibank Investment Management Group responsible for equity investment recommendations in the life sciences
BS in Engineering from Rutgers University, and an MBA from the Wharton School, University of Pennsylvania
BARRY FRANKEL
Chief Business Officer & Co-founder & Investor
Board-Certified Pediatrician and Neurologist with Special Qualification in Pediatric Neurology
Leadership positions at Astra-Zeneca, Neurobiologic Technologies, Alexion, Bioblast, NeuroTrauma, Seelos, as Senior Director, VP of Neurology, CMO and Head of R&D
Biochemist for 2 years prior to attending medical school
Twenty-two years of clinical experience in Child Neurology and twenty years of experience in the pharmaceutical industry
Chair of Pediatrics, Chair of the Board of Directors for a pediatric rehabilitation facility, Global Medical Lead for several clinical programs
Chief Medical Officer, and as Executive Vice President of Clinical Development and Head of Research and Development
Extensive expertise in clinical trial design; three such studies resulted in regulatory approvals; designed six clinical trials for orphan indications
BA from Rutgers University, MS from State University of New York Downstate Medical Center, and MD from State University of New York, Buffalo
